Background. The fibrous roots of Anemarrhena asphodeloides Bge. (FRAAB) are byproducts of the rhizome of Anemarrhena asphodeloides. Some studies have revealed secondary metabolic small molecules in FRAAB, but there are few reports on the polysaccharides of FRAAB (PFRAAB). Aim of the Study. The present study aimed to investigate the preliminary characterization and underlying mechanism of immune stimulation of PFRAAB. Materials and Methods. The crude polysaccharide of FRAAB was obtained by hot water extraction and alcohol precipitation, and PFRAAB was purified by a diethylaminoethyl-52 (DEAE-52) cellulose chromatographic column and graphene dialysis membrane. The preliminary characterization of PFRAAB was studied by ultraviolet (UV) scanning and Fourier Transform Infrared Reflection (FTIR). The molecular weight and composition of PFRAAB were analysed by high-performance gel permeation chromatography (HPGPC) and high-performance liquid chromatography (HPLC), respectively. The immune stimulation of PFRAAB was investigated by using cyclophosphamide- (CCP-) treated mice and RAW264.7 cells. Results. A water-soluble PFRAAB was obtained with a molecular weight of 115 kDa and was mainly composed of arabinose (ara), galactose (gal), glucose (glc), and mannose (man). Compared with CCP-induced mice, PFRAAB significantly ( p < 0.05 or p < 0.01 ) increased the spleen and thymus index, ameliorated injury to the spleen and thymus, and evaluated immunoglobulin levels. In addition, PFRAAB also increased the secretion of nitric oxide (NO), interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), and IL-6 in RAW264.7 cells and upregulated the expression of toll-like receptor 4 (TLR4), Myd88, nuclear factor kappa-B (NF-κB) P65, p–NF–κB P65, IKB-α, and p-IKB-α. Conclusion. PFRAAB possesses immune stimulation activity and can be used as a potential resource for immune-enhancing drugs. Our present study provides a scientific basis for the comprehensive development of Anemarrhena asphodeloides medicinal plant resources.
Objective. A network pharmacology approach was used to investigate the main active ingredients, key targets, and mechanisms of action of bitter almond antioxidants, and preliminary validation of the relevant targets was performed using molecular docking techniques. Methods. The active ingredients of bitter almond were obtained through the traditional Chinese medicine systematic pharmacology database and analysis platform (TCMSP), and the main active ingredients were screened by bioavailability (OB) and drug-like properties (DL); the GeneCards database was used to search antioxidant-related disease targets through the traditional Chinese medicine systematic pharmacology database and analysis; building a “drug-disease-target” visual network map with Cytoscape 3.9.0 software; a protein interaction (PPI) network was constructed using STRING website and core targets were screened; GO function and KEGG pathway enrichment analysis were obtained using Metoscape. Finally, SailVina software was used to molecularly dock the major active ingredients and target proteins and visualize them using PyMOL software. Results. A total of 19 antioxidant active ingredients were obtained for bitter almond, mainly stigmasterol, glycyrol, and estrone. The targets regulated by their main active ingredients were intersected with oxidative targets, and 53 intersected targets were obtained by Venn diagram, with key targets involving NR3C2, NCOA2, MAOA, ADRA2A, and CHRM1; GO analysis yielded 3616 GO entries, including 2821 biological process (BP) entries, 316 cellular component (CC) entries, and 479 molecular function (MF) entries, and 184 signalling pathways were obtained from KEGG pathway enrichment screening. The molecular docking results showed that Stigmasterol-NR3C2 binding was better. Conclusion. Stigmasterol, glycyrol, estrone, and licochalcone B in bitter almond may be the material basis of antioxidant and have better antioxidant activity; therefore, bitter almond has the characteristics of multicomponent, multitarget and multipathway.
ObjectiveTo predict the target of Seabuckthorn polysaccharides in the prevention and treatment of cervical cancer, and to explore its multi-target and multi-pathway mechanism.MethodsUsing the Swisstarget database, a total of 61 potential targets of polysaccharide active components were obtained. Cervical cancer related targets were obtained from the GeneCards database. The correlation score was greater than 5 targets for 2727; 15 intersection targets of active ingredients and disease were obtained by Venn diagram. Cytoscape3.6.0 software was used to construct the Polysaccharide composition-Target-Disease Network and Protein-Protein Interaction Networks (PPI). Cytoscape3.6.0 software was used for visualization and network topology analysis to obtain core targets. Kyoto encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) were analyzed using Metascape database. SailVina and PyMOL software were used for molecular docking to verify binding strength.ResultsA total of 15 core targets were obtained for cervical cancer. These targets are significantly enriched in HIF-1 signaling pathway, Galactose metabolism, EGFR tyrosine kinase inhibitor resistance, growth factor receptor binding, carbohydrate binding, protein homodimerization activity and other GO and KEGG entries; Molecular docking showed that ADA and GLB1 were well bound to Glucose, D-Mannose, and Galactose.ConclusionThe effect of seabuckthorn polysaccharides on the prevention and treatment of cervical cancer is characterized by multi-component, multi-target and multi-pathway, which provides scientific basis for further research on the activity of seabuckthorn polysaccharides.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.